Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text

Medicine, Bioinformatics, Oncology +17

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum et al. · Blood · 2022 · 3K citations · Full text

Medicine, Hematology, Oncology +17

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

Medicine, Pharmacotherapy, Medical Oncology +3

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations

Medicine, Hematology, Oncology +17

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9